Key result
Recent pre-clinical studies highlight potential molecular and cellular targets for intervention in radiation-induced heart disease, a late and severe side effect of thoracic radiotherapy.
Why the study?
What are the potential targets for intervention in radiation-induced heart disease based on recent pre-clinical studies?
What are the potential targets for intervention in radiation-induced heart disease based on recent pre-clinical studies?
This review summarizes recent pre-clinical studies to identify potential therapeutic targets for radiation-induced heart disease, a condition currently lacking specific treatments.
Pre-clinical targets for radiation-induced heart disease remain investigational; leaves open clinical translation pending prospective trials.
Radiotherapy of thoracic and chest wall tumors, if all or part of the heart was included in the radiation field, can lead to radiation-induced heart disease (RIHD), a late and potentially severe side effect. RIHD presents clinically several years after irradiation and manifestations include accelerated atherosclerosis, pericardial and myocardial fibrosis, conduction abnormalities, and injury to cardiac valves. The pathogenesis of RIHD is largely unknown, and a treatment is not available. Hence, ongoing pre-clinical studies aim to elucidate molecular and cellular mechanisms of RIHD. Here, an overview of recent pre-clinical studies is given, and based on the results of these studies, potential targets for intervention in RIHD are discussed.
No takes yet. Share an insight, caveat, or question.
Boerma et al. (2010) conducted a review in Radiation-Induced Heart Disease. Radiotherapy was evaluated. Recent pre-clinical studies highlight potential molecular and cellular targets for intervention in radiation-induced heart disease, a late and severe side effect of thoracic radiotherapy.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: